Experimental and emerging therapies for sepsis and septic shock
- PMID: 11772263
- DOI: 10.1517/13543784.10.8.1471
Experimental and emerging therapies for sepsis and septic shock
Abstract
The underlying principles of sepsis therapy have remained unchanged for decades. These include: prompt institution of antimicrobial agents aimed at the inciting pathogen, source control directed at removal of the infection nidus whenever possible, and support of organ dysfunction. Despite advances in antibiotics, surgical techniques and organ support technology, the morbidity and mortality from sepsis-related diseases have remained substantially unchanged (30 - 50%). Immunomodulation of the inflammatory cascade has been suggested as a crucial but inadequately addressed element in the treatment of sepsis. The list of potential therapeutic targets has been growing as more and more mediators are identified in the pathogenesis of sepsis. To date, numerous anti-inflammatory agents, found to have favourable effects in animal models of septic shock, have been tested in a number of clinical trials on thousands of patients. In this first of a three part series, we go through some of the background and current strategies in sepsis therapy. In this review, we include the two novel therapies that have shown clear survival benefit in large, randomised, placebo-controlled, multi-centre trials, low-dose steroids and recombinant activated protein C. Also included in this review are studies on antithrombin III, platelet-activating factor antagonists, complement modulators, nitric oxide synthase inhibitors and caspase inhibitors (apoptosis inhibitors).
Similar articles
-
Anti-inflammatory therapies in sepsis and septic shock.Expert Opin Investig Drugs. 2000 Jul;9(7):1651-63. doi: 10.1517/13543784.9.7.1651. Expert Opin Investig Drugs. 2000. PMID: 11060768 Review.
-
Emerging therapies for sepsis and septic shock.Ann Acad Med Singap. 1998 Sep;27(5):738-43. Ann Acad Med Singap. 1998. PMID: 9919353 Review.
-
[[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].Minerva Anestesiol. 2000 Nov;66(11 Suppl 1):3-23. Minerva Anestesiol. 2000. PMID: 11213542 Review. Italian.
-
The use of steroids in the treatment of severe sepsis and septic shock.Best Pract Res Clin Endocrinol Metab. 2011 Oct;25(5):735-43. doi: 10.1016/j.beem.2011.05.006. Best Pract Res Clin Endocrinol Metab. 2011. PMID: 21925074 Review.
-
A novel treatment strategy for sepsis and septic shock based on the interactions between prostanoids, nitric oxide, and 20-hydroxyeicosatetraenoic acid.Antiinflamm Antiallergy Agents Med Chem. 2012;11(2):121-50. doi: 10.2174/187152312803305759. Antiinflamm Antiallergy Agents Med Chem. 2012. PMID: 23013331 Review.
Cited by
-
LL-37 protects rats against lethal sepsis caused by gram-negative bacteria.Antimicrob Agents Chemother. 2006 May;50(5):1672-9. doi: 10.1128/AAC.50.5.1672-1679.2006. Antimicrob Agents Chemother. 2006. PMID: 16641434 Free PMC article.
-
Biology and pathogenesis of thrombosis and procoagulant activity in invasive infections caused by group A streptococci and Clostridium perfringens.Clin Microbiol Rev. 2003 Jul;16(3):451-62. doi: 10.1128/CMR.16.3.451-462.2003. Clin Microbiol Rev. 2003. PMID: 12857777 Free PMC article. Review.
-
Translational systems biology of inflammation: potential applications to personalized medicine.Per Med. 2010 Sep 1;7(5):549-559. doi: 10.2217/pme.10.45. Per Med. 2010. PMID: 21339856 Free PMC article.
-
Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock.Ann Surg. 2004 Feb;239(2):251-6. doi: 10.1097/01.sla.0000108673.25385.03. Ann Surg. 2004. PMID: 14745334 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical